Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
23.01.2023 12:15:02

Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital

Hardman & Co Research
Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital

23-Jan-2023 / 11:15 GMT/BST


 

 fncls.ssp?fn=download2_file&code_str=85236c70706444a4b51abd870275a9f6

 

Analyst interview  |  Life Sciences

Q&A on Shield Therapeutics (STX)  |  Positioned for profitability with Viatris deal and its additional capitaltive
 

Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews.

Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes made to the forecast and with the share price languishing what Martin expects to happen from here.

Shield Therapeutics plc is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead medicine ACCRUFeR.

Listen to the interview here

 

If you are interested in meeting the company, you can register your interest here

To contact us:

Hardman & Co
1 Frederick's Place

London

EC2R 8AE

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Analyst:

Martin Hall



+44 (0)203 693 7075

 

mh@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1541257  23-Jan-2023 

fncls.ssp?fn=show_t_gif&application_id=1541257&application_name=news&site_id=smarthouse

Analysen zu Shield Therapeutics PLCmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Shield Therapeutics PLC 0,03 -5,26% Shield Therapeutics PLC